Ritu Baral

Gautam Chukka

Gavin Clark-Gartner

Louise Chen

Ram Selvaraju

- Spyre Therapeutics, Inc. announced the closing of its underwritten public offering, which included the full exercise of the underwriters’ option to purchase additional shares.  **[1701108_6119dca2b3954e51b3b0b7dd8475ef11_0]** 
- The offering comprised **17,094,594** shares of common stock at a public offering price of **$18.50** per share.  **[1701108_6119dca2b3954e51b3b0b7dd8475ef11_0]** 
- The gross proceeds generated from the offering totaled approximately **$316.2 million**.  **[1701108_6119dca2b3954e51b3b0b7dd8475ef11_0]**

Spero Therapeutics (SPRO)